Skip to content
Triangle logo TriangleGet started
← Study library

NCT00281879 · REGISTRY CONDITION SEARCH

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2017-09-27

RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) after the transplant may help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells can make an immune response against the body's normal cells. Methotrexate, cyclosporine, tacrolimus, or methylprednisolone may stop this from happening. PURPOSE: This clinical trial is studying how well a donor stem cell transplant or donor white blood cell infusions work in treating patients with hematologic cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Disease Free Survival (DFS).

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following\*: * Acute lymphoblastic leukemia in any disease phase * Patients with any of the following high-risk features are encouraged to enroll: * Philadelphia chromosome positive disease * L3 morphology, especially in the presence of t(8;14), t(8;22), or t(2;8) * Patients not in remission at day 28 of first induction * High LDH (i.e., ≥ 300 IU/mL at presentation) * Pre-B-cell, mixed lineage, or Burkitt's markers * Relapsed in the marrow while receiving continuous chemotherapy * Within 6 months after stopping chemotherapy * Relapse in one organ or extramedullary relapses in more than one organ while still receiving chemotherapy * Hodgkin's or non-Hodgkin's lymphoma beyond first complete remission (CR) or in first CR with features of high-risk disease, including, but not limited to: * Lymphoma not in CR after 3 courses of primary therapy * Patients with bulky disease at presentation, especially bulky mediastinal disease * Patients with LDH ≥ 300 IU/mL at presentation * Patients with extranodal disease * Patients with first remission within less than 1 year * Stage IV disease at presentation, especially with marrow involvement * Patients with high-intermediate or high International Index Scores * Acute myeloid leukemia (AML) meeting the following criteria: * Beyond first remission or high-risk disease in first CR * Required multiple courses of induction therapy to achieve a remission * Had residual leukemia on day 14-28 bone marrow examination after initial induction * Patients with any cytogenetic abnormality except inv 16 or t(8;21) * Chronic myelogenous leukemia in the chronic or early accelerated phase of the disease * Patients with blast crisis that can be induced back into chronic phase may be transplanted in second chronic phase * Myelodysplastic syndromes (MDS) meeting the following requirements: * Transfusion-dependent refractory anemia (RA), RA with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocytic leukemia (CMML) * Patients with MDS that present with or evolve to AML must be re-induced back to remission prior to initiating a search for an unrelated donor NOTE: \*Patients with other hematologic malignancies not listed above, including diseases such as chronic lymphocytic leukemia (CLL), multiple myeloma, or rare pediatric malignancies, or patients who are felt to be at high-risk for relapse but who do not have features listed, may be allowed at the discretion of the investigator. * Must have failed prior stem cell transplantation * Must have a suitable unrelated allogeneic hematopoietic stem cell donor * A 5/6 match degree is acceptable for unrelated bone marrow donors * A 4/6 match degree is acceptable for unrelated cord blood units PATIENT CHARACTERISTICS: * SWOG performance status (PS) 0-2 OR * Karnofsky PS 50-100% OR * Lansky PS 50-100% * Creatinine clearance ≥ 45 mL/min * Creatinine ≤ 2.5 mg/dL * Bilirubin ≤ 2 mg/dL (abnormally high liver function tests allowed if the only source for the elevation is due to lymphoma of the liver) * AST or ALT ≤ 2 times normal (abnormally high liver function tests allowed if the only source for the elevation is due to lymphoma of the liver) * No patients at high risk of veno-occlusive disease * Not pregnant or nursing * Negative serum pregnancy test * Fertile patients must use an effective contraceptive method * DLCO ≥ 50% of predicted * FEV\_1/FVC ≥ 65% of predicted * No current congestive heart failure (CHF) and/or LVEF ≥ 45% * No myocardial infarction within the past 6 months * No unstable angina within the past 6 months * HIV negative * Life expectancy must not be limited by disease other than malignancy * No allergy to any chemotherapeutic agent included in the regimen PRIOR CONCURRENT THERAPY: * See Disease Characteristics
healthy Volunteers
false
maximum Age
60 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. intervention Names
    1. Biological: filgrastim
    2. Drug: cyclophosphamide
    3. Drug: cyclosporine
    4. Drug: methotrexate
    5. Drug: mycophenolate mofetil
    6. Drug: tacrolimus
    7. Procedure: peripheral blood stem cell transplantation
    8. Radiation: radiation therapy
    label
    Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)
    type
    ACTIVE_COMPARATOR
  2. intervention Names
    1. Biological: filgrastim
    2. Drug: busulfan
    3. Drug: cyclophosphamide
    4. Drug: cyclosporine
    5. Drug: methotrexate
    6. Drug: mycophenolate mofetil
    7. Drug: tacrolimus
    8. Procedure: peripheral blood stem cell transplantation
    label
    Busulfan and Cyclophosphamide (Cytoxan)
    type
    ACTIVE_COMPARATOR
  3. description
    On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
    intervention Names
    1. Biological: filgrastim
    2. Drug: carmustine
    3. Drug: cyclosporine
    4. Drug: cytarabine
    5. Drug: etoposide
    6. Drug: melphalan
    7. Drug: methotrexate
    8. Drug: mycophenolate mofetil
    9. Drug: tacrolimus
    10. Procedure: peripheral blood stem cell transplantation
    label
    BEAM Regimen
    type
    ACTIVE_COMPARATOR
  4. description
    A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
    intervention Names
    1. Biological: filgrastim
    2. Drug: cyclosporine
    3. Drug: fludarabine phosphate
    4. Drug: methotrexate
    5. Drug: mycophenolate mofetil
    6. Drug: tacrolimus
    7. Procedure: peripheral blood stem cell transplantation
    8. Radiation: radiation therapy
    label
    Low-Dose Fludarabine and TBI(for second stem cell donation)
    type
    ACTIVE_COMPARATOR
  5. description
    On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
    intervention Names
    1. Biological: filgrastim
    2. Drug: busulfan
    3. Drug: cyclophosphamide
    4. Drug: cyclosporine
    5. Drug: fludarabine phosphate
    6. Drug: methotrexate
    7. Drug: mycophenolate mofetil
    8. Drug: tacrolimus
    9. Procedure: peripheral blood stem cell transplantation
    label
    Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)
    type
    ACTIVE_COMPARATOR
  6. description
    If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
    intervention Names
    1. Biological: anti-thymocyte globulin
    2. Biological: filgrastim
    3. Drug: cyclosporine
    4. Drug: methotrexate
    5. Drug: methylprednisolone
    6. Drug: mycophenolate mofetil
    7. Drug: tacrolimus
    8. Procedure: peripheral blood stem cell transplantation
    9. Procedure: umbilical cord blood transplantation
    label
    ATG For Cord Blood Transplants
    type
    ACTIVE_COMPARATOR
  7. description
    Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
    intervention Names
    1. Biological: filgrastim
    2. Drug: cyclosporine
    3. Drug: methotrexate
    4. Drug: mycophenolate mofetil
    5. Drug: tacrolimus
    6. Procedure: peripheral blood stem cell transplantation
    label
    DLI (Donor Leukocyte Infusion)
    type
    ACTIVE_COMPARATOR
  8. description
    On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
    intervention Names
    1. Biological: filgrastim
    2. Drug: cyclophosphamide
    3. Drug: cyclosporine
    4. Drug: etoposide
    5. Drug: methotrexate
    6. Drug: mycophenolate mofetil
    7. Drug: tacrolimus
    8. Procedure: peripheral blood stem cell transplantation
    9. Radiation: radiation therapy
    label
    Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. ATG For Cord Blood Transplants
    description
    Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
    name
    anti-thymocyte globulin
    other Names
    1. ATG
    type
    BIOLOGICAL
  2. arm Group Labels
    1. ATG For Cord Blood Transplants
    2. BEAM Regimen
    3. Busulfan and Cyclophosphamide (Cytoxan)
    4. Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)
    5. Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)
    6. Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)
    7. DLI (Donor Leukocyte Infusion)
    8. Low-Dose Fludarabine and TBI(for second stem cell donation)
    description
    Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused. Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion.
    name
    filgrastim
    other Names
    1. G-CSF
    type
    BIOLOGICAL
  3. arm Group Labels
    1. Busulfan and Cyclophosphamide (Cytoxan)
    2. Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)
    description
    Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
    name
    busulfan
    type
    DRUG
  4. arm Group Labels
    1. BEAM Regimen
    description
    300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
    name
    carmustine
    type
    DRUG
  5. arm Group Labels
    1. Busulfan and Cyclophosphamide (Cytoxan)
    2. Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)
    3. Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)
    4. Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)
    description
    For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
    name
    cyclophosphamide
    type
    DRUG
  6. arm Group Labels
    1. ATG For Cord Blood Transplants
    2. BEAM Regimen
    3. Busulfan and Cyclophosphamide (Cytoxan)
    4. Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)
    5. Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)
    6. Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)
    7. DLI (Donor Leukocyte Infusion)
    8. Low-Dose Fludarabine and TBI(for second stem cell donation)
    description
    Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
    name
    cyclosporine
    type
    DRUG
  7. arm Group Labels
    1. BEAM Regimen
    description
    400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
    name
    cytarabine
    type
    DRUG
  8. arm Group Labels
    1. BEAM Regimen
    2. Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)
    description
    Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2. Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload.
    name
    etoposide
    type
    DRUG
  9. arm Group Labels
    1. Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)
    2. Low-Dose Fludarabine and TBI(for second stem cell donation)
    description
    Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2. Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2.
    name
    fludarabine phosphate
    type
    DRUG
  10. arm Group Labels
    1. BEAM Regimen
    description
    140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
    name
    melphalan
    type
    DRUG
  11. arm Group Labels
    1. ATG For Cord Blood Transplants
    2. BEAM Regimen
    3. Busulfan and Cyclophosphamide (Cytoxan)
    4. Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)
    5. Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)
    6. Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)
    7. DLI (Donor Leukocyte Infusion)
    8. Low-Dose Fludarabine and TBI(for second stem cell donation)
    description
    Administered on days +1, +3, and +7.
    name
    methotrexate
    type
    DRUG
  12. arm Group Labels
    1. ATG For Cord Blood Transplants
    description
    Methyl-prednisolone is administered IV as a rapid infusion.
    name
    methylprednisolone
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
200
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Determine the effectiveness of unrelated donor allogeneic hematopoietic stem cells for transplantation after conditioning for the treatment of high-risk hematopoietic malignancies. Disease-free survival: The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer.
    measure
    Number of Participants With Disease Free Survival (DFS).
    time Frame
    Duration of the study; Up to 2 years
Full study description
brief Summary
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) after the transplant may help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells can make an immune response against the body's normal cells. Methotrexate, cyclosporine, tacrolimus, or methylprednisolone may stop this from happening. PURPOSE: This clinical trial is studying how well a donor stem cell transplant or donor white blood cell infusions work in treating patients with hematologic cancer.
detailed Description
OBJECTIVES: Primary * Determine the effectiveness of unrelated donor allogeneic hematopoietic stem cells for transplantation after conditioning for the treatment of patients with high-risk hematologic malignancies. * Compare survival, disease-free survival (DFS), response rate, and toxicity rates in these patients with historical controls. * Compare the rate and severity of acute and chronic GVHD after allogeneic hematopoietic stem cell transplantation in patients with hematopoietic malignancies with historical controls transplanted with stem cells from related sibling donors * Assess engraftment, long-term hematopoietic recovery, relapse rate, and disease-free survival when allogeneic hematopoietic stem cells are used as a source of stem cells for transplantation in patients with high-risk hematological malignancies. * Assess engraftment, long-term hematopoietic recovery, and overall survival when allogeneic hematopoietic stem cells are used as a source of stem cells for transplantation in patients who have graft failure or graft rejection. * Compare engraftment, long-term hematopoietic recovery, rate of GVHD, rate of relapse, toxicity rates, overall disease-free survival and overall survival when donor leukocyte infusions (DLI) are given for patients who have disease recurrence, progression, or low donor chimerisms after unrelated stem cell transplantation or before DLI with historical controls of other donor leukocyte infusions. Secondary * Determine the quality of life of patients undergoing hematopoietic stem cell transplantation or donor leukocyte infusions from unrelated HLA genotypically-identical donors. OUTLINE: Patients are assigned to 1 of 8 treatment groups. * Group 1\*: Patients undergo total body irradiation (TBI) twice a day on days -7 to -4. Patients then receive cyclophosphamide IV over 1 hour on days -3 and -2. On day 0 patients undergo stem cell transplantation (SCT). Beginning on day 7, patients receive filgrastim (G-CSF) IV once daily until blood counts recover. * Group 2 (patients who have previously experienced dose-limiting radiotherapy): Patients receive oral busulfan 4 times daily on days -7 to -4 and cyclophosphamide IV over 1 hour on days -3 and -2. On day 0 patients undergo SCT. Beginning on day 7, patients receive G-CSF IV once daily until blood counts recover. * Group 3 (pediatric patients only): Patients receive busulfan IV 4 times daily on days -9 to -6 and cyclophosphamide IV over 1 hour and fludarabine IV over 30 minutes on days -5 to -2. On day 0 patients undergo SCT. Beginning on day 7, patients may receive G-CSF IV once daily until blood counts recover. * Group 4 (second SCT for patients who have experienced graft rejection or failure)\*: Patients receive low-dose fludarabine IV over 30 minutes on days -4 to -2. Patients then undergo low-dose TBI once followed by SCT on day 0. Beginning on day 7, patients may receive G-CSF IV once daily until blood counts recover. * Group 5 (patients who developed grade 3 cystitis after prior cyclophosphamide-containing therapy): Patients receive carmustine IV over 2 hours on day -6, etoposide IV over 2 hours and cytarabine IV over 30 minutes on days -5 to -2, and melphalan IV over 30 minutes on day -1 (BEAM). On day 0, patients undergo SCT. Beginning on day 7, patients receive G-CSF IV once daily until blood counts recover. * Group 6 (cord blood transplantation): Patients receive anti-thymocyte globulin IV once daily and methylprednisolone IV twice daily on days -3 to -1. On day 0, patients undergo an umbilical cord blood SCT. * Group 7 (patients with relapsing or progressive disease after prior transplants or low donor chimerisms)\*: Patients must not have existing graft-versus-host disease (GVHD). Patients receive donor lymphocyte infusions with conditioning chemotherapy and/or radiotherapy at the discretion of the investigator. * Group 8 (pediatric patients only)\*: Patients undergo TBI twice a day on days -7 to -5. Patients also receive etoposide IV over 24 hours on day -4 and cyclophosphamide IV over 1 hour on days -3 and -2. On day 0, patients undergo SCT. Beginning on day 7, patients may receive G-CSF IV once daily until blood counts recover. NOTE: \*Patients who have received \> 3000 cGy to the central nervous system or \> 2000 cGy to the lung or liver may not receive any regimen containing total body irradiation (TBI) All patients receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11; cyclosporine and/or tacrolimus on days -2 to 100; and/or methylprednisolone IV on days 7 to 100. Patients with an unrelated donor who experience a relapse prior to transplantation, may proceed directly to transplantation. However, if immediate transplantation from the unrelated donor is not possible, the patient must be re-induced into a complete hematological remission. Patients who experience graft failure or graft rejection after allogeneic transplantation are eligible for a second stem cell infusion from the original donor. Quality of life is assessed at baseline and at 7 days, 3 months, and 1 year after transplantation. After completion of study treatment, patients are followed periodically for survival. PROJECTED ACCRUAL: A total of 43 patients will be accrued for this study.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-1a9200b264adf1c30788
      requested nct id
      NCT00281879
      primary nct id
      NCT00281879
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      payload sha256
      a21dc82e1a7e79dcb9a7d93c34ddf6130eb7de3d7f5822f972c2c7c9172887f5
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-1a9200b264adf1c30788
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00281879
      occurrences
      1. context exact
        NCT00281879
        end
        11
        exact text
        NCT00281879
        start
        0
      offset unit
      unicode_code_points
      query cond
      Juvenile Myelomonocytic Leukemia
      query disease state id
      ds-juvenile-myelomonocytic-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      source json pointer
      /studies/59/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      55bd5630c238834de7d39e12c093c5ddb58812f7aa2ae77ba48de713513f9b25
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-1d5fd60e75b729294802
      requested nct id
      NCT00281879
      primary nct id
      NCT00281879
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
      payload sha256
      6416240279a982a58f248a3aa94ae092bcf941ef47db90aa12756672028a3008
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-1d5fd60e75b729294802
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00281879
      occurrences
      1. context exact
        NCT00281879
        end
        11
        exact text
        NCT00281879
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Myelodysplastic Neoplasms
      query disease state id
      ds-myelodysplastic-neoplasms-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-myelodysplastic-neoplasms-000.json
      source file sha256
      a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
      source json pointer
      /studies/29/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      55bd5630c238834de7d39e12c093c5ddb58812f7aa2ae77ba48de713513f9b25
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-585f74f789bfd1bf5ee6
      requested nct id
      NCT00281879
      primary nct id
      NCT00281879
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
      payload sha256
      ead90ec4505a205c7f10787b5f5c2eeb66c3c7721483831cbb17dc4a9e3f720d
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-585f74f789bfd1bf5ee6
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00281879
      occurrences
      1. context exact
        NCT00281879
        end
        11
        exact text
        NCT00281879
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Chronic Myeloid Leukemia
      query disease state id
      ds-chronic-myeloid-leukemia-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-chronic-myeloid-leukemia-000.json
      source file sha256
      193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
      source json pointer
      /studies/24/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      55bd5630c238834de7d39e12c093c5ddb58812f7aa2ae77ba48de713513f9b25
    4. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-7dc114cffdcb4270b674
      requested nct id
      NCT00281879
      primary nct id
      NCT00281879
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      payload sha256
      fc672af29a6bb397ed9e852ebd2dea860bab203875f00b560839d97592f559b2
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-7dc114cffdcb4270b674
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00281879
      occurrences
      1. context exact
        NCT00281879
        end
        11
        exact text
        NCT00281879
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hairy Cell Leukemia
      query disease state id
      ds-hairy-cell-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hairy-cell-leukemia-000.json
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      source json pointer
      /studies/17/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      55bd5630c238834de7d39e12c093c5ddb58812f7aa2ae77ba48de713513f9b25
    5. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e948e00dd8c743bd3337
      requested nct id
      NCT00281879
      primary nct id
      NCT00281879
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      6c238029921bfc3e1090a9dc12c4619323fdac1a2e187d12b023892b76f55dd2
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e948e00dd8c743bd3337
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00281879
      occurrences
      1. context exact
        NCT00281879
        end
        11
        exact text
        NCT00281879
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/433/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      55bd5630c238834de7d39e12c093c5ddb58812f7aa2ae77ba48de713513f9b25

    Preserved source evidence · Not medical advice